Falchi, L., Sureda, A., Leppä, S., Vermaat, J. S. P., Nijland, M., Christensen, J. H., Vos, S. D., Holte, H., Merryman, R. W., Lugtenburg, P. J., Abrisqueta, P., Linton, K. M., Sunkersett, G., Hoehn, D., Rana, A., Abbas, A., Marek, J., Hao, Y., Steele, A. J., Morehouse, C., Hutchings, M., Belada, D. (2025). Fixed-duration epcoritamab plus R2 drives favorable outcomes in relapsed or refractory follicular lymphoma. Blood. https://doi.org/10.1182/blood.2025029909